Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Provides an Update on ZIMHI™
April 12, 2021 07:00 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company’s New Drug Application (NDA) relating to its...
emergent logo.jpg
Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day
August 31, 2020 06:30 ET | Emergent BioSolutions
GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it is teaming up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and...
emergent logo.jpg
UPDATE -- Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
August 17, 2020 11:54 ET | Emergent BioSolutions
GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf...
emergent logo.jpg
Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
August 17, 2020 06:30 ET | Emergent BioSolutions
GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf...
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications
February 22, 2018 08:00 ET | Aegis Therapeutics LLC
SAN DIEGO, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,895,444 providing non-invasive metered nasal spray delivery of multiple...
Mucodel Pharma LLC Announces Successful Completion of Clinical Study of its Co-Gel Intranasal Naloxone Formulation
December 11, 2017 07:30 ET | Mucodel Pharma LLC
Greensboro, NC, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Mucodel Pharma LLC (“Mucodel”) today announced the successful completion of a pilot clinical study involving intranasal naloxone, a Mucodel...
Mucodel Pharma Announces Patent Allowance for Mucodel’s Co-Gel Buccal Naloxone (Exonal™)
March 15, 2017 07:45 ET | Mucodel Pharma LLC
Greensboro, NC, March 15, 2017 (GLOBE NEWSWIRE) -- Mucodel Pharma LLC (“Mucodel”) announced today that it has received a notice of allowance from the United States Patent and Trademark Office for...
Mucodel Pharma Announces Successful Completion of Buccal Naloxone Pilot Clinical Study
September 21, 2016 07:45 ET | Mucodel Pharma LLC
GREENSBORO, N.C., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Mucodel Pharma LLC (“Mucodel”) today announced the successful completion of a pilot clinical study involving buccal naloxone (Exonal™), a...
Opiant logo.jpg
Lightlake Therapeutics Inc.Announces Adapt Pharma Limited to Offer All U.S. High Schools a Free Narcan® (Naloxone Hydrochloride) Nasal Spray and Fund School-Based Opioid Overdose Education
January 27, 2016 09:00 ET | Opiant Pharmaceuticals, Inc.
NEW YORK, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
Opiant logo.jpg
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Facilitates NARCAN® (Naloxone Hydrochloride) Nasal Spray Access to 62,000 State and Local Public Entities
January 19, 2016 09:00 ET | Opiant Pharmaceuticals, Inc.
NEW YORK, Jan. 19, 2016 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...